Lv1
40 积分 2024-05-27 加入
Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer
12小时前
已完结
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
10天前
已关闭
Darinaparsin: First Approval
10天前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
11天前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
11天前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
26天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
27天前
已完结
Epidemiology of Sjögren syndrome
1个月前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
1个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
2个月前
已完结
皖公网安备34019202002308
